Clear Creek Independent School District (APRE)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Aprea Therapeutics (APRE) Upgraded to Buy: Here's What You Should Know
Aprea Therapeutics (APRE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
New Strong Sell Stocks for January 19th
APRE, NFE and CZR have been added to the Zacks Rank #5 (Strong Sell) List on January 19, 2026.
New Strong Sell Stocks for Jan. 14
APRE, CULP and PSKY have been added to the Zacks Rank #5 (Strong Sell) List on Jan.13, 2026.
Clear Creek Independent School District Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JP Joseph Pantginis HC Wainwright & Co. | 505,781.42 | $395,995.2 | $359,104.81 | -$36,890.39 | -9.32% |
| RD Robert Driscoll Wedbush | 10,497.47 | $7,449.89 | $7,453.2 | $3.31 | 0.04% |
Clear Creek Independent School District (APRE) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Clear Creek Independent School District ever had a stock split?
Clear Creek Independent School District Profile
| Biotechnology Industry | Healthcare Sector | Oren Gilad CEO | NASDAQ (CM) Exchange | 03836J102 CUSIP |
| US Country | 8 Employees | - Last Dividend | 13 Feb 2023 Last Split | 3 Oct 2019 IPO Date |
Overview
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the innovation of cancer therapeutics. It leverages the principle of synthetic lethality to target and disassemble DNA damage response pathways, aiming to introduce groundbreaking treatments for cancer. The company's strategic focus lies in identifying and commercializing novel oncology drugs that promise a transformation in cancer care. Based in Doylestown, Pennsylvania, Aprea Therapeutics is at the forefront of research in synthetic lethality-based therapies, dedicating its resources to developing drugs that could potentially improve the lives of cancer patients globally.
Products and Services
ATRN-119: This leading product candidate by Aprea Therapeutics marks a significant advancement in the treatment of advanced solid tumors, ovarian, breast, and prostate cancers. Currently in Phase I clinical trials, ATRN-119 epitomizes the company's commitment to pioneering the development of cancer therapeutics that specifically target DNA damage response pathways.
ATRN-1051: Another promising drug in development, ATRN-1051 is focused on enhancing the efficacy of cancer treatment through specifically designed mechanisms to combat advanced solid tumors. As part of the company's diverse portfolio, ATRN-1051 underscores Aprea Therapeutics' continuous strive towards innovation in oncology.
ATRN-354: With a targeted approach towards the treatment of advanced solid tumors, ATRN-354 is in the pipeline of Aprea Therapeutics' potential future offerings. Its development reflects the company's dedication to expanding its range of cancer therapeutics, delivering on the promise of synthetic lethality-based strategies.
APRE-DDRi: Standing as a testament to the innovative spirit of Aprea Therapeutics, APRE-DDRi is being developed to further the company’s portfolio of DNA damage response inhibitors. This investigational compound has the potential to pioneer new treatments that may change the standard of care for patients suffering from advanced solid tumors.
